• default-image

    InSilc Plenary Meeting – Galway, Ireland

    The Biomechanics Research Centre (BioMEC) at NUI Galway will host the next plenary meeting of the InSilc Consortium in the Alice Perry Engineering Building on the 5th and 6th July

    Read more »
  • Funding

    The project has received funding from the European Union’s Horizon 2020 research and innovation programme

    Read more »
  • The InSilc Project

    The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silicoclinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS),

    Read more »
  • InSilc Kickoff Meeting

    The kick-off meeting for InSilc project will take place on 28th November in Hotel du Lac, Ioaninna, Greece

    Read more »
  • Who are we?

    This is the excerpt for a featured post.

    Read more »

Home

The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), through building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, towards simulating their implantation performance in the individual cardiovascular physiology.

The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for mechanical behaviour, deployment and degradation, fluid dynamics, in the micro– and macroscale, and myocardial perfusion for predicting the drug-eluting BVS and vascular wall interaction, in the short– and medium/long term.

New-fig